Every pharmaceutical acquisition that includes a marketed product carries a regulatory transfer obligation that runs parallel to the corporate closing. The FDA-approved application, whether an NDA, BLA, or ANDA, is not an asset that changes hands automatically when the acquisition agreement is signed. It moves through a specific administrative process governed by federal regulation, and any interruption in that process can prevent the acquirer from distributing product, billing government programs, or operating the REMS program on which continued distribution depends. Understanding the mechanics of each approval type, the timing of effectiveness, and the downstream obligations that transfer with the approval is foundational work for any deal involving an FDA-approved drug or biologic.
1. The Regulatory Holder Concept in FDA Law
FDA approval of a drug or biologic vests in the holder of the approved application. For a New Drug Application, that is the NDA holder; for a Biologics License Application, the BLA holder; for an Abbreviated New Drug Application, the ANDA holder. The holder concept is not merely administrative. The holder bears all regulatory obligations associated with the approval, including post-market surveillance, adverse event reporting, labeling maintenance, manufacturing site management, REMS operation where required, and compliance with any post-market commitments or requirements imposed as conditions of approval.
When a pharmaceutical acquisition occurs, the legal entity that will own and operate the product after closing must become the holder of record with FDA before it can lawfully ship product under its own name, submit supplements, respond to FDA inspections as the responsible party, or receive payment from federal healthcare programs that verify holder status. The acquiring entity cannot simply inherit these rights as a matter of contract. The regulatory relationship must be formally transitioned through the procedures FDA has established for each application type.
The holder concept also defines who is responsible when things go wrong. If a serious adverse event occurs during the period between closing and FDA acknowledgment of the holder transfer, the question of who was the holder of record may determine which entity must file the MedWatch report, which entity FDA will hold accountable for any delayed reporting, and which entity's pharmacovigilance system was responsible for signal detection. Deal counsel should map this exposure carefully and ensure that interim pharmacovigilance protocols are in place from the moment the transaction closes.
The regulatory holder framework also interacts with intellectual property. The NDA or BLA holder is the entity entitled to enforce Orange Book-listed patents under the Hatch-Waxman framework, receive paragraph IV certification notices, and initiate the 30-month stay that blocks generic approval. A holder that has not been properly recognized by FDA may find itself unable to enforce those rights in a timely way. The intersection of holder status and patent exclusivity enforcement deserves specific attention in any acquisition where the product faces ongoing or anticipated generic competition.
2. NDA Holder Change Notification Under 21 CFR 314.72
The procedure for transferring an NDA is governed by 21 CFR 314.72, which requires the outgoing holder and the incoming holder to jointly notify FDA of the change. The notification must include the name and address of the new holder, a statement that the new holder has obtained the right to reference all data and information submitted with the NDA, and a statement that the new holder agrees to assume responsibility for all obligations under the NDA. The notification must be signed by both the outgoing and incoming holders, which means both parties must be prepared to execute the submission promptly at or after closing.
The joint signature requirement creates a practical challenge in deals where the seller's regulatory affairs team is demobilized at closing or where the seller has been acquired by a third party that may have limited interest in facilitating a smooth transition. Acquisition agreements should include a specific covenant requiring the seller to cooperate in preparing and signing the 21 CFR 314.72 notification, with a defined timeline measured from closing and a remedies provision if the seller fails to cooperate. Some deals include the executed notification as a closing deliverable, held in escrow pending the closing date to allow immediate filing.
The notification must be submitted as a Prior Approval Supplement or as a Changes Being Effected supplement depending on the nature of the accompanying changes, but a holder change standing alone is typically submitted as a notification rather than as a supplement requiring prior approval. FDA processes it as an administrative matter and issues an acknowledgment letter confirming the new holder of record. The acknowledgment does not constitute a new approval; it documents the administrative transfer of the existing approval. The date of that acknowledgment letter establishes the new holder's status in FDA's records and is the date from which the new holder's regulatory obligations formally run.
Counsel should also address the question of NDA-referenced manufacturing information. If the NDA contains manufacturing information submitted by contract manufacturers that the acquirer does not intend to continue using, the post-transfer supplement plan must include any required notifications or supplements to remove or change those manufacturers. Those supplements are the incoming holder's responsibility and should be identified during diligence so the acquirer can plan its post-closing regulatory calendar.
3. BLA Holder Transfer Mechanics Under 21 CFR 601.9
Biologics License Applications are governed by a separate regulatory framework, and the holder transfer procedure is found at 21 CFR 601.9. The mechanics parallel those for NDA transfers in that the outgoing and incoming holders must submit a joint notification to FDA, but BLA transfers carry additional complexity because biologics manufacturing is more closely tied to the specific establishment where manufacture occurs. The BLA licenses not only the product but the manufacturing process at the licensed establishment, and any change in manufacturing that accompanies a transfer may require separate regulatory action.
For a BLA transfer in the context of an acquisition, the incoming holder must confirm that all licensed manufacturing establishments will continue to operate under their existing licenses or that appropriate supplements have been filed to address any manufacturing changes. If the acquisition involves a transfer of manufacturing operations from the seller's facility to the acquirer's facility, that is a manufacturing site change supplement that must be approved before commercial production can begin at the new site. The BLA holder transfer notification and the manufacturing site change supplement are distinct submissions that may proceed on different timelines.
The Center for Biologics Evaluation and Research processes BLA holder transfers with somewhat different administrative protocols than CDER processes NDA transfers. Counsel and regulatory affairs professionals familiar with CBER's procedures should be engaged early in the deal process, particularly for complex biologics products or products with active post-market commitments. CBER has specific expectations about the completeness of the holder transfer package, and an incomplete submission will delay acknowledgment and extend the period of regulatory uncertainty.
Biosimilar applicants who have relied on the reference biologic product's BLA in their 351(k) applications are not directly affected by the BLA holder transfer from a legal standpoint, but the incoming holder should be aware of any pending biosimilar applications and the associated patent dance obligations. The new BLA holder inherits the obligation to participate in the patent exchange procedures under the Biologics Price Competition and Innovation Act, and any pending litigation relating to those procedures transfers to the incoming holder as well.
4. ANDA Holder Substitution Under 21 CFR 314.97
Abbreviated New Drug Applications, which govern generic drug approvals, are subject to a holder substitution procedure under 21 CFR 314.97. The regulation incorporates the change notification requirements of 21 CFR 314.72 by reference, meaning the joint notification requirement applies to ANDA transfers as it does to NDA transfers. However, ANDA transfers present distinct considerations because of the volume of applications often involved, the relationship between the ANDA and the reference listed drug, and the Orange Book implications of the holder change.
Generic drug acquisitions frequently involve portfolios of ANDAs rather than a single approved application. When a buyer acquires a generic drug company or a portfolio of ANDAs, it must submit a separate holder change notification for each ANDA in the portfolio. This creates a significant administrative undertaking that should be scoped during diligence and resourced accordingly. FDA does not process a single notification that covers multiple ANDAs; each application must be addressed individually.
For ANDAs that have been tentatively approved but not yet finally approved, the holder substitution procedure applies in the same way as for approved ANDAs. A tentative approval holder change puts the incoming holder in position to receive final approval once any blocking exclusivities or patent stays expire. Diligence should identify all tentatively approved ANDAs and their approval pathway, including any patent litigation that must be resolved before final approval can issue.
ANDA holder transfers also implicate authorized generic arrangements. If the reference NDA holder has an authorized generic agreement with the ANDA holder being acquired, that agreement is a commercial contract that may or may not survive the acquisition depending on its assignment provisions. The acquirer should review all authorized generic agreements during diligence and assess whether they create obligations or restrictions on the ANDA portfolio that affect the deal's economics.
5. Effective Date of Holder Change and Commercial Distribution Authorization
The effective date of a holder change is the date on which FDA acknowledges the notification and updates its records to reflect the new holder. Until that acknowledgment is received, the incoming holder is not the holder of record and cannot ship product under its own name as the approved holder. This creates a gap between the legal closing of the acquisition and the regulatory transfer of the approval, and that gap must be managed through interim arrangements that allow commercial distribution to continue without interruption.
The most common approach to bridging this gap is a transitional distribution agreement, under which the seller continues to ship product as the holder of record until FDA acknowledgment is received, and the acquirer purchases and distributes that product under commercial arrangements that reflect the economic ownership that has already transferred. This arrangement requires careful structuring to avoid creating a deemed transfer of the approval before the regulatory process is complete, while still allowing the acquirer to realize the commercial benefits of the product from day one of the deal.
Government pricing programs create additional complexity. Medicaid rebate agreements, Federal Supply Schedule contracts, and 340B program participation are all tied to the holder identity as reflected in FDA records. A new holder must register with the relevant programs under its own name and cannot simply step into the seller's existing program agreements. The timing of those registrations must be coordinated with the FDA acknowledgment date so that there is no period during which the product is being sold under government programs by an entity that is not the recognized holder in those programs' records.
National Drug Code numbers provide another dimension of timing complexity. NDC numbers are assigned to the holder and must be updated to reflect the new holder's labeler code after the transfer. Wholesalers, pharmacy chains, and pharmacy benefit managers rely on NDC records for formulary placement, reimbursement processing, and dispensing decisions. Updating NDC records and coordinating with trade partners on the transition timeline is operational work that must begin before closing to ensure continuity of commercial distribution.
6. Supplement Obligations After the Holder Transfer
The incoming holder assumes responsibility for all post-transfer supplement obligations immediately upon becoming the holder of record. That includes supplements already in the queue when the transfer occurs, supplements required by any post-market commitments or requirements that transferred with the approval, and supplements necessitated by manufacturing changes or labeling updates the acquirer plans to make after closing. Mapping those obligations during diligence is essential to understanding the regulatory workload the acquirer is inheriting.
Changes Being Effected supplements, both CBE-30 and CBE-immediate, allow certain manufacturing and labeling changes to be implemented before FDA approval, with notice to FDA on the specified timeline. After a holder transfer, the incoming holder may submit CBE supplements for changes that qualify under the applicable regulations. The outgoing holder's pending CBE supplements must be tracked during the transition, because a CBE that was submitted by the seller but not yet acknowledged by FDA when the transfer occurs may create ambiguity about which holder is responsible for monitoring FDA's response and implementing the change.
Prior Approval Supplements require FDA authorization before implementation and typically take longer to process. If the seller had PAS submissions pending at the time of transfer, the incoming holder must notify FDA of the holder change and coordinate with FDA on processing those pending submissions. FDA will not process a PAS submitted by the outgoing holder and issue an approval to the incoming holder without a notification linking the two, and an error in that coordination can result in a PAS approval that is issued to the wrong entity.
Annual report obligations also transfer with the approval. The incoming holder must file the next annual report under its own name and must include all the information required by 21 CFR 314.81, covering the period from the prior annual report date regardless of when during the year the transfer occurred. Deal counsel should confirm the annual report due date for each transferred application and ensure that the acquisition agreement allocates responsibility for assembling annual report information from the seller's records to support the first annual report filed by the incoming holder.
7. REMS Continuation and Operational Transfer
A Risk Evaluation and Mitigation Strategy is a post-market safety program required by FDA as a condition of approval for drugs with serious safety risks that cannot be adequately managed through labeling alone. When an NDA or BLA with a required REMS is transferred, the incoming holder assumes full operational responsibility for the REMS from the effective date of the holder transfer. That means the acquirer must be capable of operating every element of the approved REMS immediately, with no gap in program execution.
REMS programs vary significantly in complexity. A REMS with Elements to Assure Safe Use may require a restricted distribution network, mandatory prescriber certification, mandatory pharmacy certification, patient enrollment, required laboratory testing before dispensing, or some combination of all of these. Each of these elements involves contracts with third-party vendors, databases, communication systems, and trained personnel. The acquirer must assess whether it has the infrastructure to operate these elements independently or must negotiate to retain the seller's REMS infrastructure and vendor relationships through the transition period.
FDA must be notified of any proposed changes to a REMS through a REMS modification submission. The incoming holder cannot simply modify REMS operations based on its own judgment about efficiency or cost. If the acquirer intends to change REMS vendors, consolidate REMS databases, or alter any element of the program, it must submit a proposed modification and receive FDA approval before implementing the change. Planning for those modifications should begin during diligence so that the regulatory calendar is realistic.
REMS assessment submissions are required on schedules set in the approved REMS document, typically at 18 months, three years, and seven years after approval, or on a schedule specific to the program. The incoming holder must submit those assessments on schedule and must demonstrate to FDA that the REMS is operating as approved and achieving its safety objectives. An incoming holder that acquires a product with a REMS assessment due shortly after closing must have the data infrastructure and analytical capability to prepare that assessment from day one.
8. DMF Reference Rights and Confidential Information Access
Drug Master Files are voluntary submissions to FDA that hold confidential technical information about drug substances, drug products, packaging materials, excipients, and manufacturing operations. An NDA applicant typically references a DMF to incorporate the DMF holder's proprietary information into the NDA without actually disclosing that information to the NDA applicant. FDA reviews the DMF contents during the approval process but the NDA holder never sees the underlying data.
When an NDA is transferred, the incoming holder inherits the right to reference all DMFs referenced in the approved NDA. That means the incoming holder can continue to rely on those DMF references as the basis for its manufacturing process without any further action from the DMF holder, as long as the DMF holder maintains its DMF in a current and complete state. However, the incoming holder does not inherit access to the confidential contents of those DMFs. The data remains the property of the DMF holder, and the incoming NDA holder cannot review, copy, or rely on that data for any purpose other than the reference incorporated in the NDA.
This limitation creates risk when the acquiring company intends to change manufacturing operations or develop new formulations. If those activities require understanding the technical details of a referenced DMF, the acquirer will need to negotiate a separate letter of authorization from the DMF holder, a technology transfer agreement, or a commercial supply arrangement that grants access to the relevant information. Diligence should identify all referenced DMFs, assess the acquirer's need for access to the underlying information, and determine whether the relationships with DMF holders are cooperative or potentially adversarial.
DMF holders must also update their letters of authorization when an NDA changes holders. The letter of authorization grants FDA permission to review the DMF in connection with the specified NDA. When the NDA holder changes, the letter of authorization should be updated to reference the incoming holder by name. This is a procedural step that requires cooperation from the DMF holder, and an uncooperative DMF holder can complicate the post-transfer regulatory picture. Identifying potential DMF holder cooperation issues during diligence allows the deal team to address them contractually before closing.
9. Orange Book and Purple Book Updating
The Orange Book, officially the Approved Drug Products with Therapeutic Equivalence Evaluations, is FDA's published database of approved drug products. For each NDA-approved product, the Orange Book lists the NDA holder, the patent information submitted by the holder, and the therapeutic equivalence rating. When an NDA is transferred, the Orange Book must be updated to reflect the new holder. That update occurs after FDA acknowledges the holder change notification and updates its internal records, at which point the change propagates to the publicly available Orange Book database.
The Orange Book is used by pharmacists, pharmacy benefit managers, payers, and state Medicaid programs to determine substitutability of drug products. A stale Orange Book entry showing the former holder as the approved applicant can create confusion at the pharmacy and payer levels, even though the underlying approval and the therapeutic equivalence rating are unaffected by the holder change. The incoming holder should monitor the Orange Book publication following the holder transfer notification and follow up with FDA if the update is delayed beyond a reasonable period.
Patent information submitted to the Orange Book by the outgoing NDA holder transfers to the incoming holder as part of the NDA. The incoming holder becomes the patent owner of record in the Orange Book for purposes of Hatch-Waxman paragraph IV certifications. If the incoming holder is not the actual owner of the listed patents, for example where patents are held by a related entity, the Orange Book listing and the underlying patent ownership structure should be reviewed for consistency. Inaccurate Orange Book listings create exposure in Hatch-Waxman litigation, because a court may find that an NDA holder who is not the patent owner cannot pursue a 30-month stay.
The Purple Book serves a parallel function for licensed biological products. FDA maintains the Purple Book as a reference of licensed biological products and their biosimilar designations. When a BLA is transferred, the Purple Book entry must be updated to reflect the new BLA holder. The incoming holder should verify that the Purple Book has been updated after receiving FDA's acknowledgment of the holder transfer and should confirm that any reference product exclusivity periods and biosimilarity designations are correctly reflected. Errors in Purple Book listings can affect biosimilar competition dynamics and should be corrected promptly.
10. Orphan Drug Designation Transfer Under 21 CFR 316.30
Orphan drug designation is granted by FDA's Office of Orphan Products Development to sponsors who demonstrate that a product is intended to treat a rare disease or condition affecting fewer than 200,000 people in the United States. The designation provides development incentives including tax credits for clinical trial costs and, upon approval, seven years of market exclusivity during which FDA cannot approve a subsequently approved same drug for the same indication. When an orphan drug product is acquired, both the designation and the associated exclusivity must be properly transferred to the incoming holder.
The procedure for transferring an orphan drug designation is governed by 21 CFR 316.30, which requires the outgoing designee to notify FDA of the change and to provide the name and address of the incoming designee along with documentation confirming that the incoming designee has obtained the right to reference all data submitted in support of the designation. FDA will update its records to reflect the new designee and will issue a revised designation letter. This transfer notification should be submitted contemporaneously with the NDA or BLA holder change notification to avoid a mismatch in FDA's records between the approval holder and the designation holder.
Orphan exclusivity runs from the date of first approval for the designated indication and is not restarted by the holder transfer. The incoming holder is entitled to enforce the exclusivity against subsequently approved same drugs for the same indication for the remainder of the original seven-year period. However, if the designation was for a condition that has since attracted competing approvals, the exclusivity may already be limited or expired, and the deal team should assess the practical exclusivity landscape rather than assuming the full seven years remains available.
Products with orphan designation that have not yet been approved also transfer the designation when the underlying development program is acquired. In that case, the incoming designee inherits the development program obligations and the right to apply for orphan exclusivity upon approval. The acquirer should review the basis for the designation, assess whether the product still meets the patient population threshold and other designation criteria, and confirm that the designation has been maintained in good standing with annual designation renewal requirements.
11. Establishment Registration and Manufacturing Site Continuity
Every facility that manufactures, processes, packs, or holds drugs for distribution in the United States must register with FDA under the National Drug Code and establishment registration requirements. Establishment registration is done through Form FDA 2656 or the electronic equivalent in FDA's Unified Registration and Listing System. Manufacturing establishments are registered by the entity that operates them, which may or may not be the NDA or BLA holder. In an asset acquisition involving a manufacturing facility, the registration obligations follow the operational control of the facility.
When a pharmaceutical acquisition includes manufacturing facilities, the acquirer must register those facilities under its own identity before commencing manufacturing operations under its name. If the seller operated the facility and was the registered operator, the acquirer must update the registration to reflect itself as the new operator. The timing of that registration update should align with the operational transfer of the facility to avoid any period during which manufacturing activity is conducted by a party that is not the registered facility operator.
If the acquisition is structured as a stock purchase, the acquired entity continues to operate under its existing registration because the legal entity holding the registration remains the same. However, if the acquired entity is subsequently merged into the acquirer or its operations are transferred to a different legal entity within the acquirer's corporate family, the registration must be updated. Many pharmaceutical acquisitions involve post-closing integration steps that trigger registration updates, and the regulatory affairs team should map those steps and their registration implications as part of the integration planning process.
Facilities operating under Consent Decrees or subject to FDA import alerts present special concerns in an acquisition. A facility subject to a Consent Decree cannot be freely transferred; the Consent Decree defines specific obligations that run with the facility and may require FDA or court approval before the facility changes ownership or control. An import alert affecting a foreign manufacturing site will follow the site regardless of who operates it, and lifting an import alert requires demonstrating to FDA that the underlying compliance deficiencies have been corrected. Diligence must identify all facilities subject to Consent Decrees or import alerts and assess the cost and timeline of achieving compliance as part of the deal's regulatory due diligence.
12. Pharmacovigilance Handoff and Post-Market Commitment Assumption
Pharmacovigilance obligations attach to the NDA or BLA holder and require continuous monitoring of adverse events associated with the approved product. FDA requires the holder to submit expedited reports of serious, unexpected adverse events within 15 calendar days of receiving the information, and to submit periodic adverse event reports on a schedule specified in the regulations. When a holder transfer occurs, the incoming holder must be capable of processing incoming adverse event reports from the effective date of the transfer, submitting required expedited reports on time, and maintaining the pharmacovigilance database in a state that allows accurate periodic reporting.
The transition of pharmacovigilance operations is one of the most operationally complex aspects of an FDA-regulated product acquisition. The incoming holder must either establish its own pharmacovigilance infrastructure for the product or engage a contract research organization with pharmacovigilance capabilities before the transfer is effective. The adverse event database for the product, which contains all historical adverse event reports, must be transferred from the seller to the buyer in a format that is compatible with the buyer's systems and that allows accurate MedDRA coding and case narrative management.
Post-market commitments and post-market requirements are specific obligations imposed by FDA as conditions of approval or as commitments made by the outgoing holder during the approval review process. Post-market requirements are legally mandated and must be completed on the schedule FDA has established. Post-market commitments, while technically voluntary, are tracked by FDA and failure to meet them can result in regulatory action. Both categories transfer to the incoming holder, who becomes responsible for completing any studies or activities on the existing timeline.
The closure of the outgoing holder's regulatory operations creates a critical documentation challenge. The outgoing holder's regulatory files, adverse event databases, REMS records, and correspondence with FDA are all part of the historical record that the incoming holder may need to reference, defend, or produce in connection with future regulatory actions. Acquisition agreements should require the transfer of complete regulatory files in organized, searchable form, and should include representations about the completeness and accuracy of those files. Incoming holders who discover after closing that regulatory files are incomplete or inaccurate face significant remediation costs and potential exposure to FDA for gaps in required reporting periods. Structuring appropriate representations and ensuring thorough file review during diligence are the most reliable protections against that outcome.
Frequently Asked Questions
How long does an FDA NDA or BLA holder transfer typically take to become effective?
The transfer of an NDA or BLA holder does not require FDA pre-approval, but timing depends on when the written notification reaches FDA and when the agency issues its acknowledgment. Under 21 CFR 314.72 for NDAs, the outgoing and incoming holders must jointly submit a notification, and the change is generally effective upon FDA acknowledgment. FDA typically acknowledges these submissions within 30 to 90 days depending on workload, though the regulatory change of ownership date is the date of the notification submission itself once all required information is included. Counsel should structure deal closing mechanics to account for this window and plan for interim commercial distribution arrangements.
Who bears liability for REMS obligations after an FDA-approved product is transferred?
The incoming holder assumes full responsibility for Risk Evaluation and Mitigation Strategy obligations from the effective date of the holder transfer. That means the acquirer must be capable of operating every element of the REMS on day one of commercial distribution: maintaining the REMS database, executing any required elements to assure safe use, submitting REMS assessments on the existing schedule, and notifying FDA of any proposed modifications. If the REMS includes a shared system operated by a third-party vendor, the acquisition agreement must address vendor contract assignment. Diligence should map every REMS element, confirm vendor contract assignability, and verify that the incoming holder has internal or contracted infrastructure to operate the program continuously.
Can an Orange Book listing delay commercial distribution after a holder transfer?
Yes. The Orange Book reflects the approved NDA holder, and if FDA's published listing is not updated promptly, generic applicants, payers, and pharmacy systems may have inconsistent records. While a delay in the printed Orange Book update does not legally prevent the new holder from distributing product under the transferred approval, practical problems arise when wholesalers and pharmacy benefit managers verify the holder identity against the Orange Book. The new holder should submit the holder change notification alongside a request for expedited Orange Book update and maintain documentation that the FDA acknowledgment letter confirms the holder substitution, which can be provided to trade partners as interim verification.
Does the acquirer gain access to confidential Drug Master File information referenced in the transferred NDA?
Not automatically. A Drug Master File is a voluntary submission by the DMF holder, typically a raw material supplier or contract manufacturer, and its contents remain confidential to that holder. The NDA simply references the DMF by number, and FDA reviews DMF contents during the approval process without disclosing them to the NDA applicant. After a holder transfer, the incoming NDA holder inherits the right to reference the DMF by number, but does not gain access to the underlying data. If the acquirer needs visibility into DMF contents, that requires a separate letter of authorization from the DMF holder or a direct commercial arrangement granting access. Diligence should identify all DMF references and confirm that the DMF holders will issue updated letters of authorization naming the incoming NDA holder.
Is orphan drug exclusivity preserved when an orphan drug designation is transferred to an acquirer?
Yes, provided the transfer of the orphan drug designation is properly executed under 21 CFR 316.30. The exclusivity period that attaches upon product approval runs with the approved application, not with the original designee. When the designation and the corresponding NDA or BLA are transferred together, the seven-year orphan exclusivity period continues uninterrupted for the incoming holder. However, if there is any mismatch between the designation holder and the NDA or BLA holder at the time of transfer, FDA may require clarification before confirming that exclusivity applies. Deal counsel should confirm that designation records are updated contemporaneously with the approval transfer to avoid ambiguity.
What happens to unexpired PDUFA user fee obligations when an NDA or BLA is transferred?
PDUFA program fees are assessed annually against approved applications. When an NDA or BLA is transferred, any unpaid program fees assessed before the transfer effective date remain obligations of the original holder. However, program fees assessed for periods after the transfer date become the obligation of the incoming holder, because the holder on record at the time of assessment is the responsible party. Acquisition agreements should include a clear proration mechanism for user fees, a representation and warranty from the seller that all pre-closing fee assessments have been paid, and a covenant requiring the seller to cooperate with FDA's invoicing system to update the responsible party on record promptly after closing.
Does an acquirer inherit the seller's FDA inspection history and compliance status?
An acquirer inherits the regulatory record associated with the approved application and the manufacturing establishments listed in it. FDA inspection history is tied to the establishment, not to the application holder, so if the acquirer continues to manufacture at the same facilities, those facilities carry their existing inspection classifications and any outstanding warning letters or Form FDA 483 observations. The incoming holder does not inherit personal liability for prior CGMP violations at facilities it did not operate, but it does inherit operational continuity obligations. If the facilities remain the same, unresolved compliance issues can impair the new holder's ability to obtain FDA consent to new inspections or to make post-transfer manufacturing changes. Diligence should include a full inspection history review and a remediation status assessment for any facilities with outstanding compliance action.
How is pediatric exclusivity handled in a pharmaceutical acquisition?
Pediatric exclusivity under the Best Pharmaceuticals for Children Act attaches to the approved NDA and runs for six months following any existing regulatory exclusivity or patent protection. When an NDA with attached pediatric exclusivity is transferred, the exclusivity period transfers with the application to the incoming holder and continues to run from its original start date. The acquirer is also entitled to the benefit of any pending Written Requests from FDA for pediatric studies if those Written Requests are transferred as part of the transaction. The acquisition agreement should specifically represent the existence and status of any pediatric exclusivity and Written Requests, and any post-closing pediatric study obligations under outstanding Written Requests should be allocated between buyer and seller with appropriate financial terms.
Related Resources
FDA regulatory transfer mechanics sit within a broader legal framework for pharmaceutical acquisitions. The following resources address adjacent issues that arise in the same transactions:
- Life Sciences and Pharmaceutical M&A: Legal Guide - The parent guide covering the full scope of legal considerations in pharmaceutical acquisitions, from deal structure through post-closing integration.
- Contingent Value Rights in Pharmaceutical M&A: Structuring and Enforcement - How CVR agreements are structured to allocate regulatory and commercial milestone risk in pharma deals, including FDA approval milestones tied to transferred applications.
- Clinical Trial Diligence and IND/CTA Transfer in M&A - The parallel regulatory transfer issues that arise when a pipeline-stage product with an active Investigational New Drug application is part of the acquisition.
Pharmaceutical Acquisition Counsel
FDA approval transfers require coordination across regulatory affairs, legal, and commercial operations on a compressed timeline. Our M&A practice has structured and closed transactions involving NDA, BLA, and ANDA portfolios with complex transfer requirements, REMS programs, and manufacturing continuity obligations. If your transaction involves FDA-regulated products, the regulatory structure of the deal deserves as much attention as the corporate structure.
Related Practice Areas
Our attorneys handle M&A transactions and securities matters nationwide. Alex Lubyansky leads every engagement personally.